Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...

From a receding hairline to thinning crown and balding, hair loss can be a difficult personal experience for many men as they ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.